FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W345246519> ?p ?o ?g. }

• W345246519 abstract "Abstract In addition to the known cytogenetic heterogeneity of MDS, systematic application of new generation sequencing technologies (NGS) and SNP-arrays have further unraveled the complexity of MDS, revealing previously unknown somatic mutational patterns and chromosomal abnormalities. While many of the mutational events are secondary and acquired during disease progression, some may be ancestral in nature. Discovery of novel somatic defects may contribute to the understanding of molecular pathogenesis of MDS and lead to the introduction of new prognostic biomarkers or new therapeutic targets. When we performed analysis of whole exome NGS in patients with MDS and other myeloid neoplasms, including 205 from our own MDS cohort as well as 201 primary AML cases from TCGA, we noted that the BRCC3 complex gene was recurrently mutated in 9 patients (2%). These somatic mutations were confirmed by both Sanger and targeted deep sequencing. UIMC1, FAM175A, BABAM1 and FAM175B gene mutations were each found in separate single patients. The most commonly affected gene was BRCC3, found in 5 patients (1%): 1 with primary AML, 2 with CMML and 2 with MDS. There were 3 canonical mutations at exon 4 (p.R81X) and 2 in exon 1 (p.Q7X). SNP-array analysis (N=682) showed deletion of the BRCC3 complex gene in 45 patients (7%). Deletion involving the UIMC1 locus (5q35.2) and the BRCC3 locus (Xq28) were found in 31 (4.5%) and 8 (1%) patients, respectively. Evaluation of deep sequencing results demonstrates that the variant allelic frequencies of BRCC3 mutations were more than 48% in the early MDS stage, suggesting that BRCC3 mutations are initial events. The BRCC3 complex is located in the nucleus and participates in DNA double-strand break (DSB) repair. BRCC3 is a member of the JAMM/MPN+ family of zinc metalloproteases and specifically cleaves Lys-63 linked polyubiquitin chains. BRCC3 is a component of two complexes, the BRCA1-A complex and the BRISC complex. The BRCA1-A complex consists of UIMC1, FAM175A, BABAM1, BRE, BARD1, BRCC3 and BRCA1. DSB defects may be deleterious to genomic stability and instigate tumorigenesis. Clinical analysis revealed that mutations and deletions of BRCC3 complex genes were more common in MDS than in pAML (P<.01). When 684 patients genotyped for these defects were analyzed, the presence of BRCC3 complex defects was associated with shorter survival (HR=2.44 95%CI; 1.73-3.34; P<.001). The presence of BRCC3 complex gene defects affected survival in all subgroups of MDS, MDS/MPN, sAML, and pAML when analyzed separately. Overall, analysis of the additional mutational spectrum of patients with BRCC3 complex defects showed that the most frequently mutated genes were KRAS/NRAS, TET2 and U2AF1, raising the possibility of synergistic leukemogenic effects of multiple mutations. However, multivariate analysis identifies a BRCC3 complex gene defect as an independent adverse prognostic factor (HR=2.3 95%CI; 1.63-3.14; P<.001). For functional studies, we first generated a BRCC3 shRNA lentivirus vector and used it in in vitro immortalization assays utilizing a serial replating principle. BRCC3 knockdown resulted in decreased colony formation and lacked any immortalization properties. To further elucidate the functional consequences of BRCC3 lesions in the pathogenesis of MDS we performed silencing studies targeting BRCC3 in K562 cells and normal human CD34+ cells. While depletion of BRCC3 alone was not lethal, it led to enhanced etoposide-induced apoptosis. Consistent with these results, overall cell viability was substantially lower in shRNA-BRCC3–treated cells following etoposide when compared with control cells (46% vs. 55%). RPA2 expression, a single-strand DNA-binding protein used as a marker, was higher in BRCC3 knockdown cells than control cells and was further enhanced by etoposide treatment, thus indicating an increased end resection of single strand breaks. We concluded that defects in BRCC3 decrease non-homologous end joining and increased homologous recombination. In sum, our study demonstrates for the first time detection of BRCC3 complex defects, leading to impairment of DSBs repair in patients with myeloid neoplasms. Furthermore, BRCC3 defects are associated with an aggressive phenotype and shorter survival. Disclosures: Makishima: AA & MDS international foundation: Research Funding; Scott Hamilton CARES grant: Research Funding. Polprasert:MDS foundation: Research Funding. Maciejewski:NIH: Research Funding; AA/MDS foundation: Research Funding." @default.
• W345246519 created "2016-06-24" @default.
• W345246519 creator A5002411804 @default.
• W345246519 creator A5005412712 @default.
• W345246519 creator A5005451978 @default.
• W345246519 creator A5007359482 @default.
• W345246519 creator A5012723328 @default.
• W345246519 creator A5022299669 @default.
• W345246519 creator A5026679136 @default.
• W345246519 creator A5027795735 @default.
• W345246519 creator A5030942209 @default.
• W345246519 creator A5031014013 @default.
• W345246519 creator A5038219766 @default.
• W345246519 creator A5042588749 @default.
• W345246519 creator A5044213915 @default.
• W345246519 creator A5049987484 @default.
• W345246519 creator A5050620740 @default.
• W345246519 creator A5053933323 @default.
• W345246519 creator A5055740968 @default.
• W345246519 creator A5068277914 @default.
• W345246519 creator A5082561285 @default.
• W345246519 creator A5082893222 @default.
• W345246519 creator A5085974329 @default.
• W345246519 creator A5086276199 @default.
• W345246519 creator A5088167618 @default.
• W345246519 creator A5089636566 @default.
• W345246519 date "2013-11-15" @default.
• W345246519 modified "2023-10-01" @default.
• W345246519 title "Molecular Defects In BRCC3 Complex, a Novel Pathogenic Pathway In MDS" @default.
• W345246519 doi "https://doi.org/10.1182/blood.v122.21.264.264" @default.
• W345246519 hasPublicationYear "2013" @default.
• W345246519 type Work @default.
• W345246519 sameAs 345246519 @default.
• W345246519 citedByCount "1" @default.
• W345246519 countsByYear W3452465192020 @default.
• W345246519 crossrefType "journal-article" @default.
• W345246519 hasAuthorship W345246519A5002411804 @default.
• W345246519 hasAuthorship W345246519A5005412712 @default.
• W345246519 hasAuthorship W345246519A5005451978 @default.
• W345246519 hasAuthorship W345246519A5007359482 @default.
• W345246519 hasAuthorship W345246519A5012723328 @default.
• W345246519 hasAuthorship W345246519A5022299669 @default.
• W345246519 hasAuthorship W345246519A5026679136 @default.
• W345246519 hasAuthorship W345246519A5027795735 @default.
• W345246519 hasAuthorship W345246519A5030942209 @default.
• W345246519 hasAuthorship W345246519A5031014013 @default.
• W345246519 hasAuthorship W345246519A5038219766 @default.
• W345246519 hasAuthorship W345246519A5042588749 @default.
• W345246519 hasAuthorship W345246519A5044213915 @default.
• W345246519 hasAuthorship W345246519A5049987484 @default.
• W345246519 hasAuthorship W345246519A5050620740 @default.
• W345246519 hasAuthorship W345246519A5053933323 @default.
• W345246519 hasAuthorship W345246519A5055740968 @default.
• W345246519 hasAuthorship W345246519A5068277914 @default.
• W345246519 hasAuthorship W345246519A5082561285 @default.
• W345246519 hasAuthorship W345246519A5082893222 @default.
• W345246519 hasAuthorship W345246519A5085974329 @default.
• W345246519 hasAuthorship W345246519A5086276199 @default.
• W345246519 hasAuthorship W345246519A5088167618 @default.
• W345246519 hasAuthorship W345246519A5089636566 @default.
• W345246519 hasConcept C104317684 @default.
• W345246519 hasConcept C122060243 @default.
• W345246519 hasConcept C132917006 @default.
• W345246519 hasConcept C135763542 @default.
• W345246519 hasConcept C141231307 @default.
• W345246519 hasConcept C153209595 @default.
• W345246519 hasConcept C16671776 @default.
• W345246519 hasConcept C2779282312 @default.
• W345246519 hasConcept C36823959 @default.
• W345246519 hasConcept C501734568 @default.
• W345246519 hasConcept C502942594 @default.
• W345246519 hasConcept C54355233 @default.
• W345246519 hasConcept C76818968 @default.
• W345246519 hasConcept C84597430 @default.
• W345246519 hasConcept C86803240 @default.
• W345246519 hasConceptScore W345246519C104317684 @default.
• W345246519 hasConceptScore W345246519C122060243 @default.
• W345246519 hasConceptScore W345246519C132917006 @default.
• W345246519 hasConceptScore W345246519C135763542 @default.
• W345246519 hasConceptScore W345246519C141231307 @default.
• W345246519 hasConceptScore W345246519C153209595 @default.
• W345246519 hasConceptScore W345246519C16671776 @default.
• W345246519 hasConceptScore W345246519C2779282312 @default.
• W345246519 hasConceptScore W345246519C36823959 @default.
• W345246519 hasConceptScore W345246519C501734568 @default.
• W345246519 hasConceptScore W345246519C502942594 @default.
• W345246519 hasConceptScore W345246519C54355233 @default.
• W345246519 hasConceptScore W345246519C76818968 @default.
• W345246519 hasConceptScore W345246519C84597430 @default.
• W345246519 hasConceptScore W345246519C86803240 @default.
• W345246519 hasLocation W3452465191 @default.
• W345246519 hasOpenAccess W345246519 @default.
• W345246519 hasPrimaryLocation W3452465191 @default.
• W345246519 hasRelatedWork W2007913595 @default.
• W345246519 hasRelatedWork W2044208269 @default.
• W345246519 hasRelatedWork W2066314851 @default.
• W345246519 hasRelatedWork W2135898863 @default.
• W345246519 hasRelatedWork W2234270799 @default.
• W345246519 hasRelatedWork W2244206758 @default.
• W345246519 hasRelatedWork W2461867021 @default.

• next